Timing of surgery for knee injuries may not affect outcomes

  • Author: Health Informer
  • Filed under: Health News
  • Date: Dec 2,2009

Surgical treatment three weeks after injury showed similar results to those who receive early intervention

Multiple-ligament knee injuries resulting from traumatic knee dislocations – such as high impact car accidents or certain sports are uncommon, and the optimal timing of surgical repair or reconstruction has not been definitively established.

According to a new study published in the December 2009 issue of The Journal of Bone and Joint Surgery (JBJS), patients who undergo surgery more than three weeks after a multiple ligament knee injury (called chronic intervention treatment) may have comparable outcomes to those who undergo surgery within three weeks of injury (called acute intervention treatment) with regard to knee stability. Additionally, researchers found that early mobility is associated with better outcomes than immobilization in those patients who are treated within that three week time period.

“After a review of the available literature, we found that chronic intervention provides results that are at least as good as acute intervention, despite some recent studies showing that acute intervention may be better,” said lead author of the study William R. Mook, MD, who conducted the study with colleagues from the Department of Orthopaedic Surgery at the University of Virginia in Charlottesville.

Dr. Mook and his colleagues surveyed 24 retrospective studies that included 396 knees treated surgically for the most severe multiple-ligament knee injuries. Patients were managed either acutely, chronically, or with a combination of both interventions, which is called staged treatment. The researchers also studied whether the patient’s leg should or should not be mobile or immobilized after surgery.

The study found that:
– patients receiving acute intervention had less stable knees and were not able to bend their knees as far as those who were treated with chronic intervention; and
– patients who underwent staged procedures (treatment from both the acute and chronic intervention stages) reported better outcomes than those treated just early or late.

“The reasons for this are not clear. The patient population is heterogeneous, and surgery can be delayed for a variety of reasons. It is difficult to tell which procedures were delayed intentionally and which were delayed due to other medical reasons occurring as a result of their initial injury,” Dr. Mook said.

This literature review suggests the following:
– Surgical reconstructions within three weeks of the injury and those performed later provide comparable knee stability.
– In patients treated within three weeks of injury, early mobility (compared with immobilization) is associated with better outcomes. However, early surgery is highly associated with range-of-motion limitations.
– Patients reported better outcomes and fewer range-of-motion limitations with a combination of acute and chronic procedures. However, additional treatment for joint stiffness may be required in these patients.
– In patients treated within three weeks of their injury, more aggressive rehabilitation may prevent the need for additional treatment for joint stiffness.

Previous studies have indicated that early treatment provides better outcomes, but that may not be the case. “Although recent evidence suggests that acute intervention is superior to chronic interventions in all outcomes, we found that chronic intervention may provide knees with equal stability as those managed acutely,” Dr. Mook concluded.

Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity.

Source: American Academy of Orthopaedic Surgeons


Childhood lead exposure causes permanent brain damage

  • Author: Health Informer
  • Filed under: Health News
  • Date: Dec 1,2009

Prenatal or early childhood exposure to lead results in permanent brain damage in adults.

Childhood lead exposure has been associated with diminished IQ, inability to focus, poor academic performance and increased risk of criminal behavior.

Sources of residual lead include water, soil and lead-based paint.

A study using functional magnetic resonance imaging (fMRI) to evaluate brain function revealed that adults who were exposed to lead as children incur permanent brain injury. The results were presented today at the annual meeting of the Radiological Society of North America (RSNA).

“What we have found is that no region of the brain is spared from lead exposure,” said the study’s lead author, Kim Cecil, Ph.D., imaging scientist at Cincinnati Children’s Hospital Medical Center and professor of radiology, pediatrics and neuroscience at the University of Cincinnati College of Medicine. “Distinct areas of the brain are affected differently.”

The study is part of a large research project called the Cincinnati Lead Study, a long-term lead exposure study conducted through the Cincinnati Children’s Environmental Health Center, a collaborative research group funded by the National Institute of Environmental Health Sciences and U.S. Environmental Protection Agency. The Cincinnati Lead Study followed prenatal and early childhood lead exposure of 376 infants from high-risk areas of Cincinnati between 1979 and 1987. Over the course of the project, the children underwent behavioral testing and 23 blood analyses that yielded a mean blood lead level.

Lead, a common and potent poison found in water, soil and lead-based paint, is especially toxic to children’s rapidly developing nervous systems. Homes built before 1950 are most likely to contain lead-based paint, which can chip and be ingested by children.

“Lead exposure has been associated with diminished IQ, poor academic performance, inability to focus and increased risk of criminal behavior,” Dr. Cecil said.

Dr. Cecil’s study involved 33 adults who were enrolled as infants in the Cincinnati Lead Study. The mean age of the study participants, which included 14 women and 19 men, was 21 years. The participants’ mean blood lead levels ranged from 5 to 37 micrograms per deciliter with a mean of 14. Participant histories showed IQ deficiencies, juvenile delinquency and a number of criminal arrests.

Each participant underwent fMRI while performing two tasks to measure the brain’s executive functioning, which governs attention, decision making and impulse control. The imaging revealed that in order to complete a task that required inhibition, those with increased blood lead levels required activation from additional regions within the frontal and parietal lobes of the brain.

“This tells us that the area of the brain responsible for inhibition is damaged by lead exposure and that other regions of the brain must compensate in order for an individual to perform,” Dr. Cecil said. “However, the compensation is not sufficient.”

Imaging performed during a second task designed to test attention revealed an association between higher lead levels and decreased activation in the parietal region and other areas of the brain.

According to Dr. Cecil, the brain’s white matter, which organizes and matures at an early age, adapts to lead exposure, while the frontal lobe, which is the last part of the brain to develop, incurs multiple insults from lead exposure as it matures.

“Many people think that once lead blood levels decrease, the effects should be reversible, but, in fact, lead exposure has harmful and lasting effects,” she said.

Dr. Cecil believes that these findings lend support to previous reports from the Cincinnati Lead Study showing that the lasting neurological effect of lead exposure, rather than a poor social environment, is a key contributor to the subsequent cognitive and behavior problems in this group.

Co-authors are Kim M. Dietrich, Ph.D., M.S., Caleb M. Adler, M.D., James C. Eliassen, Ph.D., and Bruce P. Lanphear, M.D., M.P.H.

Source: Radiological Society of North America (RSNA)


Russia’s Hepatitis C virus drug market will grow nine percent annually

  • Author: Health Informer
  • Filed under: Health News
  • Date: Dec 1,2009

Reaching $327 Million by 2013

Sales of Roche’s Pegasys and Schering-Plough’s PegIntron Are Expected to Account for 77 Percent of the Hepatitis C Virus Drug Market in 2013 Decision Resources Expands Emerging Markets Report Series to Include Russia

Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the hepatitis C virus drug market in Russia will grow nine percent annually over the 2008 – 2013 study period, reaching $327 million by 2013. This growth will be driven mainly by increased government spending on healthcare and increased use of more-expensive therapies like pegylated interferons [peg-IFNs] (i.e., Roche’s Pegasys and Schering-Plough’s PegIntron) instead of conventional interferons (i.e., Roche’s Roferon and Schering-Plough’s Intron A).

As Russia’s gross domestic product (GDP) per capita continues to grow, both government and private healthcare spending is expected to increase as well. In 2007, the International Monetary Fund reported government spending on healthcare was only about 3.5 percent of Russia’s GDP, but the World Bank and other sources expect this number to increase to 5.5 percent of Russia’s GDP by 2013.

The new Emerging Markets report entitled Hepatitis C Virus in Russia also finds that Pegasys and PegIntron will benefit from market growth in Russia. Sales of these two agents will account for 77 percent of the total hepatitis C virus drug market in 2013, an increase from 68 percent in 2008.

“In Russia, Pegasys and PegIntron currently capture a relatively small patient share but have growth potential because physicians and patients perceive them to be more effective and safer than conventional interferons,” stated Alexandra Makarova, M.D., Ph.D., analyst at Decision Resources.

The new report is part of an expansion of the Emerging Markets report series to cover Russia. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Russia — Moscow, Saint Petersburg and Novosibirsk.

Source: Decision Resources